



The Role of Copper Intake in Bone Health: A Quantitative Analysis in Postmenopausal Spanish Women

María Luz Canal-Macías¹, Luis Manuel Puerto-Parejo¹, Jesús María Lavado-García¹, Raúl Roncero-Martín¹, Juan Diego Pedrera-Zamorano¹, Fidel López-Espuela¹, Purificación Rey-Sánchez¹, Antonio Sánchez-Fernández² and José M. Morán^{1,*}

- ¹ Metabolic Bone Diseases Research Group, Nursing Department, Nursing and Occupational Therapy College, University of Extremadura, 10003 Cceres, Spain; luzcanal@unex.es (M.L.C.-M.); luis.puerto@salud-juntaex.es (L.M.P.-P.); jmlavado@unex.es (J.M.L.-G.); rronmar@unex.es (R.R.-M.); inadroma@unex.es (L.D.P. Z.); fidellong@unex.es (FL E): prov@unex.es (R.R. S.)
- jpedrera@unex.es (J.D.P.-Z.); fidellopez@unex.es (F.L.-E.); prey@unex.es (P.R.-S.)
- ² Servicio de Tocoginecologia, Hospital San Pedro de Alcántara, 10003 Caceres, Spain; gineantonio@gmail.com
- Correspondence: jmmorang@unex.es

Abstract: (1) Background: Copper is a crucial trace element which is vital to growth and development and is especially important in bone health. Copper intake is now the focus of much broader research beyond its associations with nail growth, looking at copper's potential in contributing to bone integrity to prevent a high risk of osteoporosis as well. (2) Methods: This study included postmenopausal women from a larger longitudinal study conducted between 2019 and 2022. Bone health was assessed using three quantitative techniques: heel QUS, DXA and pQCT. Copper intake was evaluated using a 131-item, 7-day food frequency questionnaire. Data from these assessments were used to analyze the relationship between copper intake and bone health. (3) Results: In the unadjusted multiple linear regression model, associations were found between copper intake levels and both BUA (dB/MHz) and pQCT cortical + subcortical density (mg/cm³), with copper intake acting as a negative predictor in both instances. However, these associations lost statistical significance after adjusting for participant age and weight. No further associations were identified for the other parameters assessed. (4) We conclude that our study does not reveal an association between copper intake and bone health in postmenopausal Spanish women.

Keywords: copper; osteoporosis; bone mineral density; dietary intake; food frequency questionnaire

1. Introduction

Osteoporosis is a systemic, metabolic skeletal disease characterized by markedly deficient bone mineral density (BMD) and excessive susceptibility to fracture. It is characterized by an imbalance of bone remodeling dynamics, with bone resorption outpacing bone formation to cause the collapse of structural integrity and loss of mechanical resilience in the skeletal framework (Noh et al., 2020). The estimated prevalence of osteoporosis in women based on total hip BMD varies from 9% in the UK to 15% in France and Germany and up to 16–38% when spine BMD is taken into account. The rates in men based on the hip varied from 1% for the UK to 4% for Japan and increased to 3–8% when spine BMD data were included (Wade et al., 2014). More recently, the global prevalence of osteoporosis was estimated to be 18.3% overall, 23.1% in women and 11.7% in men, with the highest regional prevalence recorded in Africa at 39.5% (Salari et al., 2021). Osteoporosis imposes a heavy financial burden on the health system, with high therapy costs and decreased



Article

Academic Editors: María del Mar Molero Jurado, África Martos Martínez and María del Carmen Pérez-Fuentes

Received: 19 November 2024 Revised: 12 February 2025 Accepted: 12 February 2025 Published: 19 February 2025

Citation: Canal-Macías, M. L., Puerto-Parejo, L. M., Lavado-García, J. M., Roncero-Martín, R., Pedrera-Zamorano, J. D., López-Espuela, F., Rey-Sánchez, P., Sánchez-Fernández, A., & Morán, J. M. (2025). The Role of Copper Intake in Bone Health: A Quantitative Analysis in Postmenopausal Spanish Women. *European Journal of Investigation in Health, Psychology and Education*, 15(2), 25. https://doi.org/10.3390/ ejihpe15020025

Copyright: © 2025 by the authors. Published by MDPI on behalf of the University Association of Education and Psychology. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/

(https://creativecommons.org/ licenses/by/4.0/). productivity due to disease-related impairments. Direct medical costs, such as hospital admission, pharmacological factors and/or treatment and rehabilitative care, are considered within the overall financial impact; however, their neglect results in indirect costs, such as lost productivity time and nonproductivity time, including absenteeism and disability (Moayyeri et al., 2023).

Various factors, such as a low body mass index (BMI), female sex, advanced age and heredity, are risk factors for the onset of osteoporosis and diminished BMD (Ensrud & Crandall, 2024; Xiao et al., 2022). Adjusting for age and weight is essential in studies linking dietary intake to bone health, as both are major determinants of BMD. Age-related bone loss, driven by decreased bone formation and hormonal changes, significantly impacts BMD (Cummings & Melton, 2002). Similarly, a higher body weight is associated with greater BMD due to increased mechanical load, while a low weight elevates osteoporosis risk (Bainbridge et al., 2004; Wilsgaard et al., 2009). Without accounting for these factors, regression analyses may produce biased associations. Accurate adjustments ensure that dietary influences on bone health are correctly interpreted. In addition to the well-established risk factors, nutritional (Ilich et al., 2003), trace element and vitamin deficiencies in the development of osteoporosis are receiving increasing emphasis (Cui et al., 2024a; Gür et al., 2002; Lin et al., 2022; Pedrera-Zamorano et al., 2012).

Copper is a trace element of vital importance for sustaining human health (Scheiber et al., 2013). Copper is necessary to maintain healthy growth and development and helps nourish bones, the brain, cardiovascular function and other vital organs. The human body cannot make copper, so we must rely entirely on the diet for this essential trace mineral (Cui et al., 2024b; Fan et al., 2022; Li et al., 2023; Scheiber et al., 2014; Turnlund, 1998). There have been few observational studies regarding the association between copper and osteoporosis risk, as previous studies have largely examined the association between serum copper and osteoporosis (Chaudhri et al., 2009; Mahdavi-Roshan et al., 2015; Qu et al., 2018). However, recent studies have investigated the relationship between dietary copper intake and bone health in humans and attempted to determine how copper may be involved in safeguarding bone integrity and reducing osteoporosis risk (Chen et al., 2024; Cui et al., 2024b; Fan et al., 2022; Pasco et al., 2024). Copper is an important constituent of several physiological processes, the most important being the incorporation of copper into enzymes essential for energy metabolism and the formation of connective tissue crosslinks, particularly in bone (Rył et al., 2021). Copper supports osteogenesis by promoting the differentiation of bone mesenchymal stem cells toward bone formation rather than adipogenesis (Rodríguez et al., 2002). In addition, copper deficiency can result in Menkes disease, with osteoporosis being one of its primary adverse effects (Chen et al., 2020; Chen et al., 2024; Panichsillaphakit et al., 2022).

In nutrition-based studies, dietary copper intake is usually estimated using dietary questionnaires. These types of questionnaires are specifically used to ask for detailed information about consumption habits and then analyze nutrient content with the intake of these foods, including copper. As an example, food frequency questionnaires were used to quantify dietary copper intake in more than 10,000 participants in the Atherosclerosis Risk in Communities study and were associated with cognitive outcomes in this sample (Wei et al., 2022). Questionnaires of dietary habits have been useful in uncovering the role of copper in diverse aspects of health. The relationship between dietary copper and cardiovascular health has become a topic of research; some studies show that both deficient and excessive copper levels may influence cardiovascular disease risk (Li et al., 2023). Dietary questionnaires (Fan et al., 2022; Pasco et al., 2024) have also been used to examine copper involvement in bone health. In the present study, we aimed to add to the body of knowledge about the association between dietary copper intake and bone health. Bone health

determinations were performed using different complementary quantitative techniques, including dual-energy X-ray absorptiometry (DXA), peripheral quantitative computed tomography (pQCT) and calcaneal quantitative ultrasound (QUS). Using this approach, not only accurate BMD determinations but also the microarchitectural and mechanical characterization of bone was obtained, thereby allowing for a more specific assessment of the possible association of copper intake and bone health in postmenopausal women.

2. Materials and Methods

2.1. Participants and Sample Characteristics

This study takes place in the context of a larger longitudinal study between 2019 and 2022, during which the authors followed up with the participants. The data presented in the present study are from the cross-sectional analysis of the main study's baseline measurements. The present study included 313 postmenopausal women. The participants in this study were community-dwelling women of white European descent who were not diagnosed with functional mental or physical disability as confirmed by their primary care physician or a chronic medical specialist in their care team. These patients did not require medications known to interfere with mineral metabolism (such as oral anticoagulants, antipsychotics or corticosteroids), and they did not suffer from diabetes mellitus; liver disease; renal osteodystrophy; associated disorders of mineral metabolism; or diseases of the parathyroid, thyroid, adrenal or ovarian glands. All participants provided written informed consent. The Ethical Advisory Committee of the University of Extremadura endorsed this study. All the participants provided written informed consent in accordance with the Declaration of Helsinki.

2.2. Heel Quantitative Ultrasound (QUS) Assessment

Quantitative ultrasound (QUS) was conducted using the Sahara Clinical Sonometer (Hologic, Bedford, MA, USA) following a standardized protocol. Trained staff ensured that the participants could complete measurements on both heels, excluding those with open wounds, injuries or metal implants in the heel. Daily quality control was performed using a phantom, as per the manufacturer's guidelines. The device measured the speed of sound (SOS) and broadband ultrasound attenuation (BUA), indicators of bone health, with higher values indicating better bone quality (Sosa et al., 2002).

2.3. Dual-Energy X-Ray Absorptiometry (DXA) Assessment

BMD at the femoral neck (FN), femoral trochanter (FT) and L2–L4, as well as at a combined L2, L3 and L4 region, was measured via dual-energy X-ray absorptiometry (DXA). Body weight and body height were also recorded, and body mass index (BMI) was also calculated. BMD values were assessed via densitometry with a NORLAND XR-800 device (Norland Medical Systems Inc., Fort Atkinson, WI, USA). The BMD values are expressed in grams per square centimeter (Adams, 2013; Roncero-Martín et al., 2021).

2.4. Peripheral Quantitative Computed Tomography (pQCT) Assessment

Peripheral quantitative computed tomography (pQCT) scans of the nondominant distal forearm were obtained using a Stratec XCT-2000 scanner (Stratec Medizintechnik, Pforzheim, Germany). At 4% of the total forearm length, an image was taken with the scanner positioned at the distal end of the forearm. The data from the XCT-2000 scans were processed using the software package (version 5.50) provided by the manufacturer. The pQCT scans provide a volumetric measurement of bone mineral density and allow differentiation between trabecular and cortical bone (Roncero-Martín et al., 2021).

2.5. Assessment of Copper Intake

Total dietary copper, vitamin D, calcium and energy intake were assessed via validated frequency questionnaires, as previously described (Lavado-Garcia et al., 2012; Roncero-Martín et al., 2018). The participants completed a comprehensive 131-item, 7-day food frequency questionnaire. Food intake was quantified using a dietary scale, as well as measuring cups and spoons. The questionnaire was self-administered, with a response rate of 100%. Nutrient and energy intake values were assessed according to the Spanish food composition database (Moreiras et al., 2013).

2.6. Statistical Analysis

The median and interquartile range (IQR) were used to describe quantitative variables. For comparisons between two groups, the Mann–Whitney U test was used, and for comparisons between more than two groups, the Kruskal–Wallis test was used. The chi-square test was used to analyze the dependences of categorical variables. For some comparisons, participants were grouped on the basis of their DXA T score into low bone mass (T score < -1) or normal categories. Multiple linear regression analyses (Enter method) were performed using two models: one that was unadjusted on the basis of only copper intake quartiles and one that was adjusted for participant weight and age. Statistical significance was set at a *p* value < 0.05. All analyses were conducted using JASP software (JASP Team, 2024).

3. Results

Table 1 displays the characteristics of the study participants, categorized according to their bone health status of normal, osteopenic or osteoporotic. The prevalence of osteoporosis in the studied sample was 23%. Compared with participants without osteoporosis, those with osteoporosis were generally older and had lower BMIs, as well as smaller waist and hip measurements. Additionally, they had more years since menopause. No significant differences were observed between the groups regarding the number of pregnancies, smoking habits or dietary intake of vitamin D, calcium, energy or copper (Table 1).

Variable	Bone Health	n	Median/n	IQR/Percentage	p Value
	NORMAL	100	27.6	5.6	
BMI (kg/m ²)	OSTEOPENIA	141	26.6	5.3	< 0.001
	OSTEOPOROSIS	72	23.4	4.0	
	NORMAL	100	1.59	0.08	
Height (m)	OSTEOPENIA	141	1.58	0.07	0.088
	OSTEOPOROSIS	72	1.57	0.07	
	NORMAL	100	91	16.5	
Waist (cm)	OSTEOPENIA	141	87	13	< 0.001
	OSTEOPOROSIS	72	81	11	
Hip (cm)	NORMAL	100	107	13	
	OSTEOPENIA	141	104	10	< 0.001
	OSTEOPOROSIS	72	99	11	
	NORMAL	100	58	6.5	
Age (years)	OSTEOPENIA	141	60	6	0.019
	OSTEOPOROSIS	72	60	6.25	
Age at menarche (years)	NORMAL	100	12	3	
	OSTEOPENIA	141	13	1	0.917
	OSTEOPOROSIS	72	13	2	

Table 1. Anthropometric, biological, dietary and lifestyle characteristics of the study sample accordingto the WHO osteoporosis classification.

VariableBone HealthnMedian/nIQR/Percentage p ValueYears since menopause (years)NORMAL100710.25OSTEOPENIA141107<0.001OSTEOPOROSIS72118.25NORMAL10021Pregnancies (n)OSTEOPENIA14121OSTEOPOROSIS7221.250.306OSTEOPOROSIS72200.521Number of children (n)OSTEOPENIA14121OSTEOPOROSIS72210.521OSTEOPOROSIS72210.521OSTEOPOROSIS72210.521OSTEOPOROSIS7222/td>10.174Smoker (Y/N)*OSTEOPENIA141111/3078.7/21.30.174OSTEOPOROSIS7252/2072.2/27.80.775Vitamin D intakeNORMAL1002803600.775200 UI/day)OSTEOPENIA1412803200.775200 UI/day)OSTEOPENIA1419736510.818800 mg/day)OSTEOPENIA1419736510.818800 mg/day)OSTEOPENIA1412042.9926.50.432OSTEOPOROSIS722227.8945.50.432OSTEOPOROSIS722227.8945.50.432OSTEOPOROSIS722227.8945.50.432OSTEOPOROSIS722227.8<	V ₂ , . ¹ , 1, 1,	D II 1(1		Madler /		\$7.1.
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Variable	Bone Health	n	Median/n	IQR/Percentage	<i>p</i> value
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Voors singe menonouse	NORMAL	100	7	10.25	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(voara)	OSTEOPENIA	141	10	7	< 0.001
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(years)	OSTEOPOROSIS	72	11	8.25	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		NORMAL	100	2	1	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Pregnancies (n)	OSTEOPENIA	141	2	1	0.306
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	-	OSTEOPOROSIS	72	2	1.25	
Number of children (n)OSTEOPENIA141210.521OSTEOPOROSIS72210NORMAL10084/1684/16Smoker (Y/N)*OSTEOPENIA141111/3078.7/21.30.174OSTEOPOROSIS7252/2072.2/27.800.174Vitamin D intakeNORMAL1002803600.775200 UI/day)OSTEOPOROSIS722803200.775200 UI/day)OSTEOPOROSIS722805200.174Calcium intakeNORMAL1009325370.174(mg/day) (Reference:OSTEOPOROSIS72934.5804.50.818800 mg/day)OSTEOPOROSIS72934.5804.50.432Energy (Kcal/day)OSTEOPENIA1412042.9926.50.432OSTEOPOROSIS72227.8945.50.432OSTEOPOROSIS722227.8945.50.432		NORMAL	100	2	0	
OSTEOPOROSIS 72 2 1 NORMAL 100 84/16 84/16 Smoker (Y/N)* OSTEOPENIA 141 111/30 78.7/21.3 0.174 OSTEOPOROSIS 72 52/20 72.2/27.8 0.174 Vitamin D intake NORMAL 100 280 360 (IU/day) (Reference: OSTEOPENIA 141 280 320 0.775 200 UI/day) OSTEOPOROSIS 72 280 520 72 Calcium intake NORMAL 100 932 537 74 (mg/day) (Reference: OSTEOPENIA 141 973 651 0.818 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 74 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5 0.432	Number of children (n)	OSTEOPENIA	141	2	1	0.521
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		OSTEOPOROSIS	72	2	1	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		NORMAL	100	84/16	84/16	
OSTEOPOROSIS 72 52/20 72.2/27.8 Vitamin D intake NORMAL 100 280 360 (IU/day) (Reference: OSTEOPENIA 141 280 320 0.775 200 UI/day) OSTEOPOROSIS 72 280 520 72 280 520 Calcium intake NORMAL 100 932 537 74 75	Smoker (Y/N) *	OSTEOPENIA	141	111/30	78.7/21.3	0.174
Vitamin D intake NORMAL 100 280 360 (IU/day) (Reference: OSTEOPENIA 141 280 320 0.775 200 UI/day) OSTEOPOROSIS 72 280 520 520 Calcium intake NORMAL 100 932 537 537 (mg/day) (Reference: OSTEOPENIA 141 973 651 0.818 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 520 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 227.8 945.5 0.432		OSTEOPOROSIS	72	52/20	72.2/27.8	
(IU/day) (Reference: OSTEOPENIA 141 280 320 0.775 200 UI/day) OSTEOPOROSIS 72 280 520 Calcium intake NORMAL 100 932 537 (mg/day) (Reference: OSTEOPOROSIS 72 934.5 804.5 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5 0.432	Vitamin D intake	NORMAL	100	280	360	
200 UI/day) OSTEOPOROSIS 72 280 520 Calcium intake NORMAL 100 932 537 (mg/day) (Reference: OSTEOPENIA 141 973 651 0.818 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5	(IU/day) (Reference:	OSTEOPENIA	141	280	320	0.775
Calcium intake NORMAL 100 932 537 (mg/day) (Reference: OSTEOPENIA 141 973 651 0.818 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPOROSIS 72 2227.8 945.5	200 UI/day)	OSTEOPOROSIS	72	280	520	
(mg/day) (Reference: OSTEOPENIA 141 973 651 0.818 800 mg/day) OSTEOPOROSIS 72 934.5 804.5 NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPOROSIS 72 2227.8 945.5	Calcium intake	NORMAL	100	932	537	
800 mg/day) OSTEOPOROSIS 72 934.5 804.5 NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5 0.432	(mg/day) (Reference:	OSTEOPENIA	141	973	651	0.818
NORMAL 100 2026.8 891.7 Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5 0.432	800 mg/day)	OSTEOPOROSIS	72	934.5	804.5	
Energy (Kcal/day) OSTEOPENIA 141 2042.9 926.5 0.432 OSTEOPOROSIS 72 2227.8 945.5 0.432		NORMAL	100	2026.8	891.7	
OSTEOPOROSIS 72 2227.8 945.5	Energy (Kcal/day)	OSTEOPENIA	141	2042.9	926.5	0.432
		OSTEOPOROSIS	72	2227.8	945.5	
Copper intake NORMAL 100 1.1 2.1	Copper intake	NORMAL	100	1.1	2.1	
(mg/day) (Reference OSTEOPENIA 141 1.3 3.1 0.789	(mg/day) (Reference	OSTEOPENIA	141	1.3	3.1	0.789
1.3 mg/day) OSTEOPOROSIS 72 1.3 2.1	1.3 mg/day)	OSTEOPOROSIS	72	1.3	2.1	

Table 1. Cont.

Comparisons were performed using the nonparametric Kruskal-Wallis test. * The chi-square test was used for the variable "smoker".

To further explore this analysis, participants were subsequently grouped into low (T score < -1) and normal bone mass categories. Comparative analysis between groups with low bone mass and those with normal bone mass revealed significant differences in physical and age-related characteristics. Participants with lower bone mass presented significantly different values for body mass index, height, waist circumference, hip circumference and age. Conversely, no statistically significant differences were observed in reproductive variables or in the dietary intake of specific nutrients, including vitamin D, calcium or copper, or caloric intake (Table 2).

Table 2. Anthropometric, biological, dietary and lifestyle characteristics of the study sample with low or normal BMD.

Variable	Bone Health	n	Median/n	IQR/Percentage	p Value
DNI $(1, \dots, 2)$	LOW	212	25.7	5.5	-0.001
BMI (kg/m ⁻)	NORMAL	101	27.6	5.5	<0.001
Hoight (m)	LOW	212	1.58	0.07	0.020
Tiergin (III)	NORMAL	101	1.59	0.08	0.039
Maist (am)	LOW	212	85	13.3	<0.001
Walst (CIII)	NORMAL	101	91	16	<0.001
Hip (cm)	LOW	212	103	12	<0.001
rup (cm)	NORMAL	101	107	13	<0.001
Age (years)	LOW	212	60	6	0.002
rige (years)	NORMAL	101	58	7	0.005
Δq_{0} at menarche (years)	LOW	212	13	2	0 760
Age at menalthe (years)	NORMAL	101	12	3	0.709

(Reference: 1.3 mg/day)

Variable	Bone Health	n	Median/n	IQR/Percentage	<i>p</i> Value	
	LOW	212	10	7.3	0.822	
rears since menopause (years)	NORMAL	101	7	10		
$\mathbf{D}_{\mathbf{r}}$	LOW	212	2	1	0.000	
Pregnancies (n)	NORMAL	101	2	1	0.093	
Number of children (n)	LOW	212	2	1	0.189	
	NORMAL	101	2	0		
$C_{\rm res} = 1 + m \left(\frac{1}{\sqrt{2}} \right) $	LOW	212	162/50	76.4/23.6	0.116	
Smoker (1/N)	NORMAL	101	85/16	84.2/15.8		
Vitamin D intake (IU/day)	LOW	212	280	360	0.70	
(Reference: 200 UI/day)	NORMAL	101	280	400	0.72	
Calcium intake (mg/day)	LOW	212	968	692.3	0.50	
(Reference: 800 mg/day)	NORMAL	101	934	535	0.53	
Eporeu (Keel/deu)	LOW	212	2156	943.6	0.244	
Energy (NCal/day)	NORMAL	101	2007.4	898.7	0.344	
Copper intake (mg/day)	LOW	212	1.3	2.8	0 ==	

101

Table 2. Cont.

NORMAL

The comparison between groups was conducted using the nonparametric Mann-Whitney U test. * The chi-square test was used for the variable "smoker".

1.2

2.2

To further investigate the potential role of copper intake in bone health, participants were divided into quartiles on the basis of their copper intake levels. The results of the quantitative analysis of bone health using QUS, DXA and pQCT, stratified by copper intake quartiles, are presented in Table 3. No significant differences were observed in the quantitative bone health measurements among the copper dietary intake groups.

Table 3. Bone health analysis using quantitative techniques according to copper dietary intake quartiles.

Variable	Copper Dietary Intake Quartile	n	Median	IQR	<i>p</i> Value
	Q1 < 0.719	79	105.3	14.4	
	Q2 (0.719–1.213)	78	104.8	15.6	0.045
DUA (dd/ MHZ)	Q3 > 1.213–3.403	78	106	11.5	0.065
	Q4 > 3.403	77	102	13.7	
	Q1 < 0.719	79	1541.3	37.7	
	Q2 (0.719–1.213)	78	1540	35.4	0 (74
505 (m/s)	Q3 > 1.213–3.403	78	1543.8	35.7	0.674
	Q4 > 3.403	77	1538.1	30.9	
	Q1 < 0.719	79	307.3	83.3	
$\sim OCT$ Total Damaita (~ 2)	Q2 (0.719–1.213)	78	295.6	69.7	0.500
pQC1 Iotal Density (mg/cm ³)	Q3 > 1.213–3.403	78	298.5	77.7	0.528
	Q4 > 3.403	78	297.8	56.6	
	Q1 < 0.719	79	160.3	57.8	
pQCT Trabecular Density	Q2 (0.719–1.213)	78	146.7	60.9	0.445
(mg/cm^3)	Q3 > 1.213–3.403	78	161.2	51.3	0.445
	Q4 > 3.403	78	166.1	42.2	
	Q1 < 0.719	79	431	133.6	
pQCT Cortical + Subcortical	Q2 (0.719–1.213)	78	414.1	92.2	0.171
Density (mg/cm ³)	Q3 > 1.213-3.403	78	403	123.7	0.171
	Q4 > 3.403	78	413.1	82.6	

0.57

7 of 13	3
---------	---

Variable	Copper Dietary Intake Quartile	n	Median	IQR	<i>p</i> Value
	Q1 < 0.719	79	299.7	51.4	
pQCT Total Area (mm ²)	Q2 (0.719–1.213)	78	300.4	50.1	
	Q3 > 1.213–3.403	78	302.0	50.8	0.929
	Q4 > 3.403	78	298.5	60.7	
	Q1 < 0.719	79	134.7	23.2	
$\mathbf{O} = \mathbf{T} + \mathbf{I} + $	Q2 (0.719–1.213)	78	135.1	22.7	0.005
pQC1 Irabecular Area (mm ²)	Q3 > 1.213–3.403	78	135.8	23.0	0.925
	Q4 > 3.403	78	134.2	27.2	
	Q1 < 0.719	79	165	28.3	
pQCT Cortical + Subcortical	Q2 (0.719–1.213)	78	165.3	27.3	0.171
Area (mm ²)	Q3 > 1.213–3.403	78	166.7	27.8	0.171
	Q4 > 3.403	78	164.4	33.7	
	Q1 < 0.719	79	0.888	0.227	
\mathbf{D}	Q2 (0.719–1.213)	78	0.905	0.255	0.077
DXA Lumbar Spine (g/cm ²)	Q3 > 1.213-3.403	78	0.907	0.208	0.866
	Q4 > 3.403	78	0.913	0.191	
	Q1 < 0.719	79	0.865	0.256	
$DY \wedge L2 (\pi/m^2)$	Q2 (0.719–1.213)	78	0.893	0.258	0.044
DXA L2 (g/cm ⁻)	Q3 > 1.213-3.403	78	0.889	0.206	0.944
	Q4 > 3.403	78	0.891	0.178	
	Q1 < 0.719	79	0.885	0.269	
$DY \wedge L^2 \left(\frac{1}{2} \left(\frac{1}{2} \right)^2 \right)$	Q2 (0.719–1.213)	78	0.931	0.285	0.001
DAA L3 (g/ cm^{-})	Q3 > 1.213-3.403	78	0.909	0.227	0.821
	Q4 > 3.403	78	0.914	0.200	
	Q1 < 0.719	79	0.892	0.203	
$DVAIA(a/am^2)$	Q2 (0.719–1.213)	78	0.919	0.258	07()
DAA L4 (g/ cm ⁻)	Q3 > 1.213-3.403	78	0.917	0.233	0.762
	Q4 > 3.403	78	0.893	0.222	
	Q1 < 0.719	79	0.750	0.171	
DXA Femoral Neck (g/cm ²)	Q2 (0.719–1.213)	78	0.770	0.137	0.2(0
	Q3 > 1.213-3.403	78	0.754	0.157	0.369
	Q4 > 3.403	78	0.738	0.111	
	Q1 < 0.719	79	0.609	0.144	
DXA Femoral Trochanter	Q2 (0.719–1.213)	78	0.604	0.154	0.407
(g/cm^2)	Q3 > 1.213-3.403	78	0.605	0.153	0.427
	Q4 > 3.403	78	0.588	0.120	

Table 3. Cont.

 $Group\ comparisons\ were\ conducted\ using\ the\ nonparametric\ Kruskal-Wallis\ test.$

In the unadjusted multiple linear regression model, associations were observed exclusively between copper intake levels and both BUA (dB/MHz) and pQCT cortical + subcortical density (mg/cm³), with copper intake serving as a negative predictor in both associations (Table 4). However, these associations were not significant after the models were adjusted for participant age and weight. No additional associations were detected for the remaining parameters evaluated.

 Table 4. Multiple linear regression models.

Variable BUA (dB/MHz)	Model 1 β (95% CI)	p Value	Model 2 β (95% CI)	<i>p</i> Value
Q1 < 0.719	Reference		Reference	
Q2 (0.719–1.213)	-1.654(-5.158; 1.849)	0.353	-0.899 (-4.149; 2.350)	
Q3 > 1.213–3.403	-2.481(-5.984; 1.022)	0.164	-1.860(-5.107; 1.388)	
Q4 > 3.403	-4.427 (-7.942; -0.912)	0.014	-1.851 (-5.185; 1.483)	

Table 4. Cont.

BUA (dBMHz) β (95% CD) p Value β (95% CD) p Value SOS (m/s) Q1 < 0.719 Neterence Q2 (0.719-1.213) -1.148 (-12.157, 9.81) 0.838 - Q2 (0.719-1.213) -1.148 (-12.157, 9.81) 0.838 - - - Q2 (0.719-1.213) (-1.1375, 9.8.352) 0.629 - - - PQCT Total Density (mg/cm ³) Reference -	Variable	Model 1		Model 2	
$\begin{array}{llllllllllllllllllllllllllllllllllll$	BUA (dB/MHz)	β (95% CI)	<i>p</i> Value	β (95% CI)	<i>p</i> Value
$ \begin{array}{cccc} Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.148 (-1.2157, 9.861) & 0.838 \\ Q4 > 3.403 & -2.713 (-1.3758, 332) & 0.629 \\ pQCT Total Density (mg/cm3) & -2.713 (-1.3758, 332) & 0.629 \\ pQCT Total Density (mg/cm3) & -2.713 (-1.3758, 332) & 0.629 \\ Q2 (0.719-1.213) & (-8.44 (-26.14, 9.2.99) & 0.348 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.394 \\ Q4 > 3.403 & -7.681 (-25.381, 10.013) & 0.961 \\ Q4 > 3.403 & 4.250 (-8.782, 17.283) & 0.961 \\ Q4 > 3.403 & 4.250 (-6.782, 17.283) & 0.961 \\ Q4 > 3.403 & -2.879 (-54.95, -2.626) & -4.154 (-28.253, 19.944) & 0.735 \\ Q1 < 0.719 & Reference & Reference \\ Q2 (0.719-1.213) & -1.02.6 (-36.42, 15.902) & 0.4411 & -4.154 (-28.253, 19.944) & 0.735 \\ Q1 < 0.719 & Reference & -1.164 \\ Q1 < 0.719 & -2.879 (-22.75, 8158) & 0.593 \\ Q3 > 1.213 - 3.403 & -2.209 (-17.66, 13.236) & 0.779 \\ Q4 > 3.403 & -2.209 (-17.66, 13.246) & 0.779 \\ Q4 > 3.403 & -3.425 (-10.383, 3.484) & 0.328 \\ pQCT Totabcular Area (mm2) & -1.751 (-8.684; 5.182) & 0.620 \\ Q3 > 1.213 - 3.403 & -3.45 (-10.383, 3.484) & 0.328 \\ pQCT Contical - Subcortical Area (mm2) & -1.751 (-8.684; 5.182) & 0.620 \\ Q4 > 3.403 & -3.45 (-10.383, 3.484) & 0.328 \\ pQCT Contical - Subcortical Area (mm2) & -2.424 (-10.073; 6.125) & 0.577 \\ Q2 (0.719 - 1.213) & -1.751 (-8.684; 5.182) & 0.574 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.007) & 0.593 \\ Q4 > 3.403 & -0.$	SOS(m/s)				
$\begin{array}{ccccc} Q2 (0.719-1.213) & -1.148 (-12.157; 9.861) & 0.838 \\ Q4 > 3.403 & -2.713 (-13.758; 8.332) & 0.629 \\ pQCT Tiotal Density (mg/cm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & (-8.44 (-26.14; 9.249) & 0.348 \\ Q3 > 1215-3.403 & -7.681 (-25.38; 10.013) & 0.394 \\ Q4 > 3.403 & -1.3.431 (-31.13; 4.263) & 0.366 \\ PQCT Trabecular Density (mg/cm3) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -3.991 (-17.023; 9.042) & 0.547 \\ Q3 > 1213-3.403 & 0.326 (-12.707; 13.358) & 0.961 \\ Q4 > 3.403 & 4.250 (-8.782; 17.283) & 0.951 \\ Q4 > 3.403 & 4.250 (-8.782; 17.283) & 0.951 \\ Q4 > 3.403 & 4.250 (-8.782; 17.283) & 0.522 \\ PQCT Cortical + Subcortical Density (mg/cm3) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -10.26 (-5.6.42; 15.902) & 0.441 & -4.154 (-28.253; 19.944) & 0.735 \\ Q3 > 1.213-3.403 & -13.16 (-39.33; 12.997) & 0.323 & -8.582 (-32.662; 15.498) & 0.484 \\ Q4 > 3.403 & -28.79 (-54.95; -0.266) & 0.031 & -10.412 (-35.059; 14.235) & 0.406 \\ PQCT Trabal Area (mm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -4.203 (-19.66; 11.253) & 0.593 \\ Q3 > 1.213-3.403 & -2.299 (-17.66; 13.246) & 0.779 \\ Q4 > 3.403 & -2.297 (-2.275, 8.158) & 0.354 \\ PQCT Trabecular Area (mm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.751 (-8.684; 5.182) & 0.620 \\ Q3 > 1.213-3.403 & -3.48 (-10.38; 3.484) & 0.328 \\ PQCT Cortical + Subcortical Area (mm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.751 (-8.684; 5.182) & 0.577 \\ Q3 > 1.213-3.403 & -0.024 (-10.975; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -0.024 (-10.975; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -0.024 (-0.079; 0.313 & 0.393 \\ PQCT Cortical + Subcortical Area (mm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.0040; 0.070) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.0079; 0.313) & 0.393 \\ DXA Lumbar Spine (Q/cm2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.0040; 0.070) & 0.593 \\ Q4 > 3.403 & -0.024 (-0.0079; 0.313) & 0.393 \\ DXA Lumbar Spine (Q/cm2) \\ Q4 > 3.403 & -0.024 (-0.0079; 0.303 \\ Q4 > 3.403 & -0.024 (-0.0079; 0.313) & 0.798 \\ Q4 > 3.403 &$	Q1 < 0.719	Reference			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q2 (0.719–1.213)	-1.148(-12.157; 9.861)	0.838		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q3 > 1.213–3.403	1.076 (-9.933; 12.086)	0.848		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q4 > 3.403	-2.713 (-13.758; 8.332)	0.629		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	pQCT Total Density (mg/cm^3)				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q1 < 0.719	Reference			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q2 (0.719–1.213)	(-8.44 (-26.14; 9.249))	0.348		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q3 > 1.213–3.403	-7.681 (-25.38; 10.013)	0.394		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q4 > 3.403	-13.431 (-31.13; 4.263)	0.136		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	pQCT Trabecular Density (mg/cm ³)				
$\begin{array}{ccccc} Q2 \ (0.719-1.213) & -3.991 \ (-17.023; 9.042) & 0.547 \\ Q3 > 1.213-3.403 & 0.326 \ (-12.707; 13.358) & 0.961 \\ Q4 > 3.403 & 4.250 \ (-8.782; 17.283) & 0.522 \\ pQCT Cortical + Subcortical Density \ (mg/cm^3) & \\ Q1 < 0.719 & Reference & Reference \\ Q2 \ (0.719-1.213) & -10.26 \ (-36.42; 15.902) & 0.441 & -4.154 \ (-28.253; 19.944) & 0.735 \\ Q3 > 1.213-3.403 & -33.16 \ (-39.33; 12.997) & 0.323 & -8.582 \ (-32.662; 15.498) & 0.484 \\ Q4 > 3.403 & -28.79 \ (-54.95; -2.626) & 0.031 & -10.412 \ (-35.059; 14.235) & 0.406 \\ pQCT Total Area \ (mm^2) & \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719-1.213) & -4.203 \ (-19.66; 11.253) & 0.593 \\ Q3 > 1.213-3.403 & -2.209 \ (-17.66; 13.246) & 0.779 \\ Q4 > 3.403 & -7.297 \ (-22.75; 8.158) & 0.354 \\ pQCT Toabcular Area \ (mm^2) & \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719-1.213) & -1.751 \ (-8.684; 5.182) & 0.620 \\ Q3 > 1.213-3.403 & -0.978 \ (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -0.978 \ (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -0.978 \ (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -0.978 \ (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -0.978 \ (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -0.454 \ (-1.033; 3.484) & 0.328 \\ pQCT Cortical + Subcortical Area \ (mm^2) & \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719-1.213) & -2.424 \ (-10.973; 6.125) \ 0.577 \\ Q3 > 1.213-3.403 & -1.404 \ (-9.954; 7.145) \ 0.747 \\ Q4 > 3.403 & -1.404 \ (-9.954; 7.145) \ 0.747 \\ Q4 > 3.403 & -0.024 \ (-1.0077; 0.031) \ 0.393 \\ DXA \ Lumbar Spine \ (g/cm^2) & \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719-1.213) & 0.015 \ (-0.040; 0.070) \ 0.593 \\ Q3 > 1.213-3.403 & -0.013 \ (-0.067; 0.012) \ 0.393 \\ DXA \ Humbar Spine \ (g/cm^2) & \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719-1.213) & 0.015 \ (-0.040; 0.070) \ 0.593 \\ Q3 > 1.213-3.403 & -0.005 \ (-0.045; 0.050) \ 0.527 \\ Q3 > 1.213-3.403 & -0.005 \ (-0.045; 0.012) \ 0.180 \\ \end{array}$	Q1 < 0.719	Reference			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q2 (0.719–1.213)	-3.991 (-17.023; 9.042)	0.547		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q3 > 1.213–3.403	0.326 (-12.707; 13.358)	0.961		
pQCT Cortical + Subcortical Density (mg/cm ³) Reference Q2 (0.719-1.213) -10.26 ($-36.42;$ 15.902) 0.41 -4.154 ($-28.253;$ 19.944) 0.735 Q3 > 1.213-3.403 -13.16 ($-39.33;$ 12.997) 0.323 -8.582 ($-28.262;$ 15.998) 0.484 Q4 > 3.403 -28.79 ($-54.95;$ -2.626) 0.031 -10.412 ($-35.059;$ 14.235) 0.406 pQCT Total Area (mm ²) Reference Q2 (0.719-1.213) -4.203 ($-19.66;$ 11.253) 0.593 Q3 > 1.213-3.403 -2.209 ($-17.66;$ 13.246) 0.779 Q4 > 3.403 -7.297 ($-22.75;$ 8.158) 0.354 pQCT Trabecular Area (mm ²) Reference Q Q Q1 < 0.719 Reference Q2 (0.719-1.213) -1.751 ($-8.684;$ 5.182) 0.620 0.324 0.324 0.328 pQCT Cortical + Subcortical Area Mm ² Reference Q Q Q (1.0719) Reference Q Q (2.0719-1.213) -0.2424 ($-10.973;$ 6.125) 0.577 Q (3.9) 1.213-3.403 -0.4484 ($-1.033;$ 4.065) 0.303 DXA Lumbar Spine (g/cm ²) Reference Q Q (2.0719-1.213) 0.015 ($-0.040;$ 0.070) 0.593 Q (2.0719-1.213) 0.015 ($-0.040;$ 0.070	Q4 > 3.403	4.250 (-8.782; 17.283)	0.522		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	pQCT Cortical + Subcortical Density				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	(mg/cm^3)				
$\begin{array}{c ccccc} Q2 (0.719-1.213) & -10.26 (-36.42; 15.902) & 0.421 & -4.154 (-28.253; 19.944) & 0.735 \\ Q3 > 1.213-3.403 & -13.16 (-39.33; 12.997) & 0.323 & -8.582 (-32.662; 15.498) & 0.484 \\ Q4 > 3.403 & -28.79 (-54.95; -2.626) & 0.031 & -10.412 (-35.059; 14.235) & 0.406 \\ pQCT Total Area (mm2) & Reference \\ Q2 (0.719-1.213) & -4.203 (-19.66; 11.253) & 0.593 \\ Q3 > 1.213-3.403 & -2.209 (-17.66; 13.246) & 0.779 \\ Q4 > 3.403 & -7.297 (-22.75; 8.158) & 0.354 \\ pQCT Trabecular Area (mm2) & Reference \\ Q2 (0.719-1.213) & -1.751 (8.684; 5.182) & 0.620 \\ Q3 > 1.213-3.403 & -0.978 (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -3.45 (-10.383; 3.484) & 0.328 \\ pQCT Cotical + Subortical Area (mm2) & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -1.404 (-9.954; 7.145) & 0.747 \\ Q4 > 3.403 & -4.484 (-1.033; 4.065) & 0.303 \\ DXA Lumbar Spine (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -2.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -1.0045 (-0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.005 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.002 (-0.079; 0.031) & 0.393 \\ DXA Hip (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.002 (-0.079; 0.031) & 0.393 \\ DXA Hip (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.033) & 0.798 \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.033) & 0.798 \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.033) & 0.798 \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213-3.403 & -0.0026 (-0.044; 0.012) & 0.180 \\ \end{array}$	Q1 < 0.719	Reference		Reference	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Q2 (0.719–1.213)	-10.26 (-36.42; 15.902)	0.441	-4.154(-28.253; 19.944)	0.735
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q3 > 1.213–3.403	-13.16 (-39.33; 12.997)	0.323	-8.582 (-32.662; 15.498)	0.484
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q4 > 3.403	-28.79 (-54.95; -2.626)	0.031	-10.412 (-35.059 ; 14.235)	0.406
$\begin{array}{ccccc} Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -4.203 (-19.66; 11.253) & 0.593 \\ Q3 > 1.213-3.403 & -2.209 (-17.66; 13.246) & 0.779 \\ Q4 > 3.403 & -7.297 (-22.75; 8.158) & 0.354 \\ pQCT Trabecular Area (mm^2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.751 (-8.684; 5.182) & 0.620 \\ Q3 > 1.213-3.403 & -0.978 (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -3.45 (-10.383; 3.484) & 0.328 \\ pQCT Cortical + Subcortical Area (mm^2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -1.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -4.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -4.484 (-1.033; 4.065) & 0.303 \\ DXA Lumbar Spine (g/cm^2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ DXA Lumbar Spine (g/cm^2) \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ DXA Hip (g/cm^2) \\ Q1 < 0.719 & Reference \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213-3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 (-0.064; 0.012) & 0.180 \\ \end{array}$	pQCT Total Area (mm ²)				
$\begin{array}{ccccccc} Q2 \left(0.719 - 1.213 \right) & -4.203 \left(-19.66; 11.253 \right) & 0.593 \\ Q3 > 1.213 - 3.403 & -2.209 \left(-17.66; 13.246 \right) & 0.779 \\ Q4 > 3.403 & -7.297 \left(-22.75; 8.158 \right) & 0.354 \\ \end{array}$	Q1 < 0.719	Reference			
$\begin{array}{cccc} Q_3 > 1.213 - 3.403 & -2.209 (-17.66; 13.246) & 0.779 \\ Q_4 > 3.403 & -7.297 (-22.75; 8.158) & 0.354 \\ \end{array}$	Q2 (0.719–1.213)	-4.203 (-19.66; 11.253)	0.593		
$\begin{array}{c c} Q4 > 3.403 & -7.297 \left(-22.75; 8.158\right) & 0.354 \\ pQCT Trabecular Area (mm^2) & \\ Q1 < 0.719 & Reference & \\ Q2 (0.719 - 1.213) & -1.751 \left(-8.684; 5.182\right) & 0.620 \\ Q3 > 1.213 - 3.403 & -0.978 \left(-7.911; 5.955\right) & 0.782 \\ Q4 > 3.403 & -3.45 \left(-10.383; 3.484\right) & 0.328 \\ pQCT Cortical + Subcortical Area & \\ (mm^2) & \\ Q1 < 0.719 & Reference & \\ Q2 (0.719 - 1.213) & -2.424 \left(-10.973; 6.125\right) & 0.577 \\ Q3 > 1.213 - 3.403 & -1.404 \left(-9.954; 7.145\right) & 0.747 \\ Q4 > 3.403 & -1.404 \left(-9.954; 7.145\right) & 0.303 \\ DXA Lumbar Spine (g/cm^2) & \\ Q1 < 0.719 & Reference & \\ Q2 (0.719 - 1.213) & 0.015 \left(-0.040; 0.070\right) & 0.593 \\ Q3 > 1.213 - 3.403 & -0.0013 \left(-0.069; 0.042\right) & 0.630 \\ Q4 > 3.403 & -0.024 \left(-0.079; 0.031\right) & 0.393 \\ DXA Hip (g/cm^2) & \\ Q1 < 0.719 & Reference & \\ Q1 < 0.719 & Reference & \\ Q2 (0.719 - 1.213) & 0.012 \left(-0.026; 0.050\right) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.0025 \left(-0.044; 0.012\right) & 0.180 \\ \end{array}$	Q3 > 1.213–3.403	-2.209 (-17.66; 13.246)	0.779		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q4 > 3.403	-7.297 (-22.75; 8.158)	0.354		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	pQCT Trabecular Area (mm ²)				
$\begin{array}{ccccc} Q2 \left(0.719 - 1.213 \right) & -1.751 \left(-8.684; 5.182 \right) & 0.620 \\ Q3 > 1.213 - 3.403 & -0.978 \left(-7.911; 5.955 \right) & 0.782 \\ Q4 > 3.403 & -3.45 \left(-10.383; 3.484 \right) & 0.328 \\ pQCT Cortical + Subcortical Area \\ (mm^2) & & & & & & & & & & & & & & & & & & &$	Q1 < 0.719	Reference			
$\begin{array}{cccc} Q3 > 1.213 - 3.403 & -0.978 (-7.911; 5.955) & 0.782 \\ Q4 > 3.403 & -3.45 (-10.383; 3.484) & 0.328 \\ pQCT Cortical + Subcortical Area \\ (mm^2) & & & \\ Q1 < 0.719 & Reference \\ Q2 (0.719 - 1.213) & -2.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213 - 3.403 & -1.404 (-9.954; 7.145) & 0.747 \\ Q4 > 3.403 & -4.484 (-1.033; 4.065) & 0.303 \\ DXA Lumbar Spine (g/cm^2) & & \\ Q1 < 0.719 & Reference \\ Q2 (0.719 - 1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213 - 3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ DXA Hip (g/cm^2) & & \\ Q1 < 0.719 & Reference \\ Q2 (0.719 - 1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.002 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.005 (-0.044; 0.012) & 0.180 \\ \end{array}$	Q2 (0.719–1.213)	-1.751 (-8.684; 5.182)	0.620		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q3 > 1.213–3.403	-0.978(-7.911; 5.955)	0.782		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Q4 > 3.403	-3.45 (-10.383; 3.484)	0.328		
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	pQCT Cortical + Subcortical Area				
$\begin{array}{cccc} Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & -2.424 (-10.973; 6.125) & 0.577 \\ Q3 > 1.213-3.403 & -1.404 (-9.954; 7.145) & 0.747 \\ Q4 > 3.403 & -4.484 (-1.033; 4.065) & 0.303 \\ \hline DXA Lumbar Spine (g/cm2) & Reference \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ \hline DXA Hip (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213-3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 (-0.064; 0.012) & 0.180 \\ \hline \end{array}$	(mm ²)				
$\begin{array}{ccccccc} Q2 \left(0.719 - 1.213\right) & -2.424 \left(-10.973; 6.125\right) & 0.577 \\ Q3 > 1.213 - 3.403 & -1.404 \left(-9.954; 7.145\right) & 0.747 \\ Q4 > 3.403 & -4.484 \left(-1.033; 4.065\right) & 0.303 \\ \hline DXA Lumbar Spine (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 \left(0.719 - 1.213\right) & 0.015 \left(-0.040; 0.070\right) & 0.593 \\ Q3 > 1.213 - 3.403 & -0.013 \left(-0.069; 0.042\right) & 0.630 \\ Q4 > 3.403 & -0.024 \left(-0.079; 0.031\right) & 0.393 \\ \hline DXA Hip (g/cm2) & \\ Q1 < 0.719 & Reference \\ Q2 \left(0.719 - 1.213\right) & 0.012 \left(-0.026; 0.050\right) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 \left(-0.043; 0.033\right) & 0.798 \\ Q4 > 3.403 & -0.026 \left(-0.064; 0.012\right) & 0.180 \\ \hline \end{array}$	Q1 < 0.719	Reference			
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Q2 (0.719–1.213)	-2.424 (-10.973; 6.125)	0.577		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Q3 > 1.213–3.403	-1.404(-9.954; 7.145)	0.747		
$\begin{array}{c c c c c c c } DXA \ Lumbar \ Spine (g/cm^2) & Reference \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ DXA \ Hip (g/cm^2) & & & & \\ Q1 < 0.719 & Reference \\ Q2 (0.719-1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213-3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 (-0.064; 0.012) & 0.180 \\ \end{array}$	Q4 > 3.403	-4.484(-1.033; 4.065)	0.303		
$\begin{array}{cccc} Q1 < 0.719 & \text{Reference} \\ Q2 (0.719-1.213) & 0.015 (-0.040; 0.070) & 0.593 \\ Q3 > 1.213-3.403 & -0.013 (-0.069; 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 (-0.079; 0.031) & 0.393 \\ DXA \text{ Hip } (g/cm^2) & & & & \\ Q1 < 0.719 & \text{Reference} & & & \\ Q2 (0.719-1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213-3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 (-0.064; 0.012) & 0.180 \\ \end{array}$	DXA Lumbar Spine (g/cm ²)				
$\begin{array}{cccc} Q2 \ (0.719 - 1.213) & 0.015 \ (-0.040; \ 0.070) & 0.593 \\ Q3 > 1.213 - 3.403 & -0.013 \ (-0.069; \ 0.042) & 0.630 \\ Q4 > 3.403 & -0.024 \ (-0.079; \ 0.031) & 0.393 \\ \\ DXA \ Hip \ (g/cm^2) \\ Q1 < 0.719 & Reference \\ Q2 \ (0.719 - 1.213) & 0.012 \ (-0.026; \ 0.050) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 \ (-0.043; \ 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 \ (-0.064; \ 0.012) & 0.180 \\ \end{array}$	Q1 < 0.719	Reference			
$\begin{array}{cccc} Q3 > 1.213 - 3.403 & -0.013 \left(-0.069; 0.042\right) & 0.630 \\ Q4 > 3.403 & -0.024 \left(-0.079; 0.031\right) & 0.393 \\ \\ DXA \ Hip (g/cm^2) \\ Q1 < 0.719 & Reference \\ Q2 \left(0.719 - 1.213\right) & 0.012 \left(-0.026; 0.050\right) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 \left(-0.043; 0.033\right) & 0.798 \\ Q4 > 3.403 & -0.026 \left(-0.064; 0.012\right) & 0.180 \\ \end{array}$	Q2 (0.719–1.213)	0.015 (-0.040; 0.070)	0.593		
$\begin{array}{ccc} Q4 > 3.403 & -0.024 \left(-0.079; 0.031\right) & 0.393 \\ \\ DXA \ Hip (g/cm^2) & & & \\ Q1 < 0.719 & Reference \\ Q2 \left(0.719 - 1.213\right) & 0.012 \left(-0.026; 0.050\right) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 \left(-0.043; 0.033\right) & 0.798 \\ Q4 > 3.403 & -0.026 \left(-0.064; 0.012\right) & 0.180 \end{array}$	Q3 > 1.213–3.403	-0.013(-0.069; 0.042)	0.630		
$\begin{array}{c c} DXA \ \text{Hip} \ (\text{g/cm}^2) \\ Q1 < 0.719 \\ Q2 \ (0.719 - 1.213) \\ Q3 > 1.213 - 3.403 \\ Q4 > 3.403 \\ \end{array} \begin{array}{c} \text{Reference} \\ 0.012 \ (-0.026; 0.050) \\ -0.005 \ (-0.043; 0.033) \\ -0.026 \ (-0.064; 0.012) \\ 0.180 \\ \end{array}$	Q4 > 3.403	-0.024(-0.079; 0.031)	0.393		
$\begin{array}{ccc} Q1 < 0.719 & Reference \\ Q2 (0.719 - 1.213) & 0.012 (-0.026; 0.050) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 (-0.043; 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 (-0.064; 0.012) & 0.180 \end{array}$	DXA Hip (g/cm ²)				
$\begin{array}{ccc} Q2 \ (0.719 - 1.213) & 0.012 \ (-0.026; \ 0.050) & 0.527 \\ Q3 > 1.213 - 3.403 & -0.005 \ (-0.043; \ 0.033) & 0.798 \\ Q4 > 3.403 & -0.026 \ (-0.064; \ 0.012) & 0.180 \end{array}$	Q1 < 0.719	Reference			
$\begin{array}{ccc} Q3 > 1.213 - 3.403 & -0.005 \left(-0.043; 0.033 \right) & 0.798 \\ Q4 > 3.403 & -0.026 \left(-0.064; 0.012 \right) & 0.180 \end{array}$	Q2 (0.719–1.213)	0.012 (-0.026; 0.050)	0.527		
Q4 > 3.403 $-0.026 (-0.064; 0.012)$ 0.180	Q3 > 1.213–3.403	-0.005(-0.043; 0.033)	0.798		
	Q4 > 3.403	-0.026 (-0.064 ; 0.012)	0.180		

Model 1 (unadjusted). Model 2 adjusted for age and weight.

4. Discussion

In the present study, we explored the relationship between dietary copper intake and bone health in postmenopausal Spanish women via a comprehensive array of quantitative densitometric tests. No associations were observed between copper intake and the various bone health measurements included in this study. To our knowledge, this is the first study to evaluate the relationship between dietary copper intake and bone health using a battery of densitometric measures. Few epidemiological studies have examined serum copper levels and their relationship with bone health. Both lower and higher serum copper levels are associated with lower BMD (by %) in the total femur and femoral neck and an increased fracture risk, particularly in men (Qu et al., 2018).

A total of 728 postmenopausal women reporting a history of osteoporosis were investigated for relationships between the serum levels of nine important minerals and osteoporosis. Serum copper levels were significantly related to the diminished BMD of the

total femur, femoral neck and lumbar spine, which suggests that mineral deficiency is a risk factor for osteoporosis in postmenopausal women (Okyay et al., 2013). The serum copper levels did not significantly differ among the healthy, osteopenic and osteoporotic groups of 107 postmenopausal women. Additionally, serum copper levels were not related to BMD, and copper did not contribute directly to or hinder the bone health of these postmenopausal women (Arikan et al., 2011).

A recent study reported negative findings regarding the effects of serum copper levels on bone health in younger populations, highlighting the need for further research to clarify these associations (Liu et al., 2024). Therefore, previous studies have investigated the extent to which serum copper correlates with BMD but not the extent to which dietary copper intake correlates with the development of osteoporosis or low bone mass.

Recently, observational studies evaluating the relationship between dietary copper intake and bone health as assessed by DXA measurements have been published. A study investigating the relationship between copper intake and bone health analyzed data from 8224 adults in the United States. A higher copper intake was associated with increased BMD at the femur and spine and a reduced risk of osteoporosis. Participants in the highest copper intake quartile had a 59% lower risk of osteoporosis than did those in the lowest quartile, indicating a positive role of dietary copper intake in bone health (Fan et al., 2022). A second study explored the association of BMD with copper and selenium intake in 522 women, 20 to 88 years of age. Lower BMD at various skeletal sites was associated with low intakes of both trace elements. After potential confounders were adjusted for, a low copper intake was linked to a 1.8–4.0% reduction in BMD, supporting the role of copper in maintaining optimal bone health (Pasco et al., 2024). In this context, a controlled trial investigated the effects of copper supplementation on vertebral trabecular bone mineral density (VTBMD) over two years in 73 healthy women aged 45–56 years. The participants were randomly assigned to receive 3 mg of copper or a placebo. Although no significant effects on copper status biomarkers were observed, the copper-supplemented group showed no change in VTBMD, whereas the placebo group experienced a significant reduction in VTBMD (Eaton-Evans et al., 1996). Other studies have reported less favorable findings as regards the role of copper and other minerals in bone health. In a study of postmenopausal women with osteoporosis and osteopenia, it was discovered that the dietary magnesium, zinc, calcium and copper intake was lower than the recommended levels. Nevertheless, no difference was found in the dietary intake of copper between groups with osteopenia and osteoporosis (Mahdavi-Roshan et al., 2015). Importantly, however, the results of this study are in agreement with those of the current study while illustrating a potential statistical power concern. The sample sizes included in studies recently published by Fan et al. (2022) and Pasco et al. (2024) are noteworthy, and it cannot be ruled out that the absence of statistically significant findings in our study may be related to a possible type II error. Our findings here, suggesting that no associations were observed, could be due to insufficient power to detect subtle effects in our sample. The study by Pasco et al. 2024 reported a post hoc computed effect size strikingly similar to that reported in our own research. Secondly, they also used tertiles, which allowed for increased statistical power through increasing the sample size in separate groups so that the analysis was more sensitive in detecting conceivable effects.

It is evident from the analysis of the scientific literature currently available (mainly from observational studies) that there is a discrepancy in studies regarding how copper intake is associated with bone health. This divergence in results is based on the observational nature of most of the studies, the populations and the methodologies of analysis used in each case. We, therefore, consider it a priority that the next studies to be carried out approach the subject from a longitudinal point of view, assessing BMD and the risk of fracture in the context of copper intake in the medium and long term. We hope that these studies can help to establish without a doubt the existence of causality and try to understand the mechanisms by which copper participates in the regulation of bone metabolism. In addition, a systematic review of the available literature could help to clarify the relationship. These approaches could help to clarify in the future the need to improve or not improve dietary recommendations regarding copper intake or to discover possible therapeutic interventions that favor adequate copper intake, which is related to greater benefits in bone health in postmenopausal women.

We acknowledge that our study has several limitations inherent to observational research. One of the primary limitations is the use of a dietary recall questionnaire to assess copper intake, which is subject to recall bias and may not accurately capture long-term dietary habits. Additionally, the sample size in our study was relatively small, which poses a recognized risk of type II error, potentially limiting the ability to detect statistically significant associations. Despite these limitations, our study has notable strengths. This study is the first to incorporate data from three distinct quantitative techniques for assessing bone health in postmenopausal Spanish women, offering a comprehensive evaluation of bone mineral density across different methodologies. The use of three different quantitative techniques, QUS, DXA and pQCT, improves the completeness of the study. This is achieved through a multidimensional assessment of bone health in the women studied. Each technique individually determines a different characteristic, and together they represent a complementary approach to bone health. On the one hand, QUS offers an accessible, portable, non-ionizing option to assess the mechanical properties of bone tissue and fracture risk. On the other hand, DXA is recognized as the gold standard for the diagnosis of osteoporosis worldwide, providing accurate BMD determinations in those skeletal regions that are critical for diagnosis (lumbar spine and hip). Finally, pQCT analysis provides accurate information on bone microarchitecture, trabecular and cortical bone compartments are analyzed, and information on bone density and volume is acquired.

5. Conclusions

We conclude that our study does not reveal an association between copper intake and bone health in postmenopausal Spanish women. In light of recent findings from other studies, our results likely reflect a situation of possible type II error, attributed to insufficient statistical power. We recommend that these data be utilized in future studies, particularly within the context of meta-analyses, to further elucidate the potential role of copper intake in bone health in postmenopausal women.

Author Contributions: Conceptualization, J.M.M. and J.D.P.-Z.; methodology, M.L.C.-M.; L.M.P.-P., F.L.-E., J.M.L.-G., P.R.-S., R.R.-M. and A.S.-F.; formal analysis, J.M.M. and J.D.P.-Z.; data curation, M.L.C.-M.; writing—original draft preparation, J.M.M. and J.D.P.-Z.; writing—review and editing, J.M.M. and J.D.P.-Z. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Junta de Extremadura, Consejería de Economía e Infraestructuras, Spain, Fondo Europeo de Desarrollo Regional, "Una manera de hacer Europa", under grant numbers IB18042 and IB18044.

Institutional Review Board Statement: This study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the University of Extremadura (protocol code: 84/2018; date of approval: 6 July 2018).

Informed Consent Statement: Informed consent was obtained from all participants involved in this study.

Data Availability Statement: The dataset analyzed in the current study is not publicly available due to national data regulations and for ethical reasons, including that we do not have the explicit written consent of the study volunteers to make their deidentified data available at the end of the study. However, datasets and SPSS statistical analyses can be requested by sending a letter to the corresponding author.

Acknowledgments: The authors would like to thank Alejandro Herrador for his technical assistance in the development of this study. We would also like to thank all the women who participated in this study in such difficult times for their generous participation.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

- Adams, J. E. (2013). Dual-energy X-ray absorptiometry. In G. Guglielmi (Ed.), Osteoporosis and bone densitometry measurements (pp. 101–122). Springer. [CrossRef]
- Arikan, D. C., Coskun, A., Ozer, A., Kilinc, M., Atalay, F., & Arikan, T. (2011). Plasma selenium, zinc, copper and lipid levels in postmenopausal Turkish women and their relation with osteoporosis. *Biological Trace Element Research*, 144(1–3), 407–417. [CrossRef]
- Bainbridge, K. E., Sowers, M., Lin, X., & Harlow, S. D. (2004). Risk factors for low bone mineral density and the 6-year rate of bone loss among premenopausal and perimenopausal women. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 15(6), 439–446. [CrossRef]
- Chaudhri, M. A., Kemmler, W., Harsch, I., & Watling, R. J. (2009). Plasma copper and bone mineral density in osteopenia: An indicator of bone mineral density in osteopenic females. *Biological Trace Element Research*, 129(1–3), 94–98. [CrossRef] [PubMed]
- Chen, J., Jiang, Y., Shi, H., Peng, Y., Fan, X., & Li, C. (2020). The molecular mechanisms of copper metabolism and its roles in human diseases. *Pflugers Archiv: European Journal of Physiology*, 472(10), 1415–1429. [CrossRef]
- Chen, M., Jia, L., & Gao, R. (2024). Association between dietary copper, iron, zinc, selenium intake and osteopenia or osteoporosis in elderly hypertensive patients: A retrospective cohort study. *Frontiers in Nutrition*, *11*, 1419379. [CrossRef]
- Cui, A., Xiao, P., Wei, X., Wen, H., Liang, S., Wang, P., He, J., & Zhuang, Y. (2024a). Associations between serum selenium and bone mineral density in 8–19-year-old children and adolescents: NHANES 2013–2018. *Biological Trace Element Research*, 202(5), 1928–1936. [CrossRef] [PubMed]
- Cui, A., Yan, J., Li, H., Fan, Z., Wei, X., Wang, H., & Zhuang, Y. (2024b). Association between dietary copper intake and bone mineral density in children and adolescents aged 8–19 years: A cross-sectional study. *PLoS ONE*, *19*(10), e0310911. [CrossRef] [PubMed]
- Cummings, S. R., & Melton, L. J. (2002). Epidemiology and outcomes of osteoporotic fractures. *Lancet*, 359(9319), 1761–1767. [CrossRef] [PubMed]
- Eaton-Evans, J., Mcllrath, E. M., Jackson, W. E., McCartney, H., & Strain, J. J. (1996). Copper supplementation and the maintenance of bone mineral density in middle-aged women. *The Journal of Trace Elements in Experimental Medicine*, 9(3), 87–94. [CrossRef]
- Ensrud, K. E., & Crandall, C. J. (2024). Osteoporosis. Annals of Internal Medicine, 177(1), ITC1–ITC16. [CrossRef] [PubMed]
- Fan, Y., Ni, S., & Zhang, H. (2022). Associations of copper intake with bone mineral density and osteoporosis in adults: Data from the national health and nutrition examination survey. *Biological Trace Element Research*, 200(5), 2062–2068. [CrossRef] [PubMed]
- Gür, A., Colpan, L., Nas, K., Cevik, R., Saraç, J., Erdoğan, F., & Düz, M. Z. (2002). The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin. *Journal of Bone and Mineral Metabolism*, 20(1), 39–43. [CrossRef]
- Ilich, J. Z., Brownbill, R. A., & Tamborini, L. (2003). Bone and nutrition in elderly women: Protein, energy, and calcium as main determinants of bone mineral density. *European Journal of Clinical Nutrition*, 57(4), 554–565. [CrossRef] [PubMed]
- JASP Team. (2024). JASP (Version 0.19.3) [Computer software], JASP Team.
- Lavado-Garcia, J. M., Calderon-Garcia, J. F., Moran, J. M., Canal-Macias, M. L., Rodriguez-Dominguez, T., & Pedrera-Zamorano, J. D. (2012). Bone mass of Spanish school children: Impact of anthropometric, dietary and body composition factors. *Journal of Bone* and Mineral Metabolism, 30(2), 193–201. [CrossRef]
- Li, X., Dehghan, M., Tse, L. A., Lang, X., Rangarajan, S., Liu, W., Hu, B., Yusuf, S., Wang, C., & Li, W. (2023). Associations of dietary copper intake with cardiovascular disease and mortality: Findings from the Chinese Perspective Urban and Rural Epidemiology (PURE-China) Study. *BMC Public Health*, 23(1), 2525. [CrossRef] [PubMed]
- Lin, S., Yang, F., Ling, M., & Fan, Y. (2022). Association between bone trace elements and osteoporosis in older adults: A cross-sectional study. *Therapeutic Advances in Musculoskeletal Disease*, 14, 1759720X221125984. [CrossRef]

- Liu, H., Bao, M., Liu, M., Deng, F., Wen, X., Wan, P., Lin, X., Dong, G., Li, Z., & Han, J. (2024). The Association between Serum Copper and Bone Mineral Density among Adolescents Aged 12 to 19 in the United States. *Nutrients*, *16*(3), 453. [CrossRef] [PubMed]
- Mahdavi-Roshan, M., Ebrahimi, M., & Ebrahimi, A. (2015). Copper, magnesium, zinc and calcium status in osteopenic and osteoporotic post-menopausal women. *Clinical Cases in Mineral and Bone Metabolism: The Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 12(1), 18–21.* [CrossRef]
- Moayyeri, A., Warden, J., Han, S., Suh, H. S., Pinedo-Villanueva, R., Harvey, N. C., Curtis, J. R., Silverman, S., Multani, J. K., & Yeh, E. J. (2023). Estimating the economic burden of osteoporotic fractures in a multinational study: A real-world data perspective. *Osteoporosis International*, *34*(12), 2121–2132. [CrossRef]
- Moreiras, O., Carbajal, A., Cabrera, L., & Cuadrado, C. (2013). Tablas de composición de alimentos, 16 edición, edit. Pirámide, España.
- Noh, J.-Y., Yang, Y., & Jung, H. (2020). Molecular mechanisms and emerging therapeutics for osteoporosis. *International Journal of Molecular Sciences*, 21(20), 7623. [CrossRef] [PubMed]
- Okyay, E., Ertugrul, C., Acar, B., Sisman, A. R., Onvural, B., & Ozaksoy, D. (2013). Comparative evaluation of serum levels of main minerals and postmenopausal osteoporosis. *Maturitas*, 76(4), 320–325. [CrossRef] [PubMed]
- Panichsillaphakit, E., Kwanbunbumpen, T., Chomtho, S., & Visuthranukul, C. (2022). Copper-histidine therapy in an infant with novel splice-site variant in the ATP7A gene of Menkes disease: The first experience in South East Asia and literature review. *BMJ Case Reports*, 15(4), e247937. [CrossRef] [PubMed]
- Pasco, J. A., Anderson, K. B., Williams, L. J., Stuart, A. L., Hyde, N. K., & Holloway-Kew, K. L. (2024). Dietary intakes of copper and selenium in association with bone mineral density. *Nutrients*, *16*(16), 2777. [CrossRef] [PubMed]
- Pedrera-Zamorano, J. D., Calderon-García, J. F., Roncero-Martin, R., Mañas-Nuñez, P., Moran, J. M., & Lavado-García, J. M. (2012). The protective effect of calcium on bone mass in postmenopausal women with high selenium intake. *Journal of Nutrition, Health and Aging*, 16(9), 743–748. [CrossRef] [PubMed]
- Qu, X., He, Z., Qiao, H., Zhai, Z., Mao, Z., Yu, Z., & Dai, K. (2018). Serum copper levels are associated with bone mineral density and total fracture. *Journal of Orthopaedic Translation*, 14, 34–44. [CrossRef]
- Rodríguez, J. P., Ríos, S., & González, M. (2002). Modulation of the proliferation and differentiation of human mesenchymal stem cells by copper. *Journal of Cellular Biochemistry*, 85(1), 92–100. [CrossRef]
- Roncero-Martín, R., Aliaga, I., Moran, J. M., Puerto-Parejo, L. M., Rey-Sánchez, P., de la Luz Canal-Macías, M., Sánchez-Fernández, A., Pedrera-Zamorano, J. D., López-Espuela, F., Vera, V., Cerrato-Carretero, P., & Lavado-García, J. M. (2021). Plasma fatty acids and quantitative ultrasound, DXA and pQCT derived parameters in postmenopausal Spanish women. *Nutrients*, 13(5), 1454. [CrossRef]
- Roncero-Martín, R., Vera, I. A., Moreno-Corral, L. J., Moran, J. M., Lavado-Garcia, J. M., Pedrera-Zamorano, J. D., & Pedrera-Canal, M. (2018). Olive oil consumption and bone microarchitecture in Spanish women. *Nutrients*, 10(8), 968. [CrossRef] [PubMed]
- Rył, A., Miazgowski, T., Szylińska, A., Turoń-Skrzypińska, A., Jurewicz, A., Bohatyrewicz, A., & Rotter, I. (2021). Bone health in aging men: Does zinc and cuprum level matter? *Biomolecules*, *11*(2), 237. [CrossRef]
- Salari, N., Ghasemi, H., Mohammadi, L., Behzadi, M. hasan, Rabieenia, E., Shohaimi, S., & Mohammadi, M. (2021). The global prevalence of osteoporosis in the world: A comprehensive systematic review and meta-analysis. *Journal of Orthopaedic Surgery and Research*, *16*(1), 609. [CrossRef] [PubMed]
- Scheiber, I., Dringen, R., & Mercer, J. F. B. (2013). Copper: Effects of deficiency and overload. *Metal Ions in Life Sciences*, 13, 359–387. [CrossRef] [PubMed]
- Scheiber, I. F., Mercer, J. F. B., & Dringen, R. (2014). Metabolism and functions of copper in brain. *Progress in Neurobiology*, 116, 33–57. [CrossRef] [PubMed]
- Sosa, M., Saavedra, P., Muñoz-Torres, M., Alegre, J., Gómez, C., González-Macías, J., Guañabens, N., Hawkins, F., Lozano, C., Martínez, M., Mosquera, J., Pérez-Cano, R., Quesada, M., Salas, E., & GIUMO Study Group. (2002). Quantitative ultra-sound calcaneus measurements: Normative data and precision in the Spanish population. Osteoporosis International: A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 13(6), 487–492. [CrossRef] [PubMed]
- Turnlund, J. R. (1998). Human whole-body copper metabolism. *The American Journal of Clinical Nutrition*, 67(5 Suppl.), 960S–964S. [CrossRef] [PubMed]
- Wade, S. W., Strader, C., Fitzpatrick, L. A., Anthony, M. S., & O'Malley, C. D. (2014). Estimating prevalence of osteoporosis: Examples from industrialized countries. Archives of Osteoporosis, 9, 182. [CrossRef]
- Wei, J., Gianattasio, K. Z., Bennett, E. E., Stewart, J. D., Xu, X., Park, E. S., Smith, R. L., Ying, Q., Whitsel, E. A., & Power, M. C. (2022). The associations of dietary copper with cognitive outcomes. *American Journal of Epidemiology*, 191(7), 1202–1211. [CrossRef] [PubMed]

- Wilsgaard, T., Emaus, N., Ahmed, L. A., Grimnes, G., Joakimsen, R. M., Omsland, T. K., & Berntsen, G. R. (2009). Lifestyle impact on lifetime bone loss in women and men: The Tromsø Study. *American Journal of Epidemiology*, 169(7), 877–886. [CrossRef] [PubMed]
- Xiao, P. L., Cui, A. Y., Hsu, C. J., Peng, R., Jiang, N., Xu, X. H., Ma, Y. G., Liu, D., & Lu, H. D. (2022). Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: A systematic review and meta-analysis. Osteoporosis International, 33(10), 2137-2153. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.